Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
The Motley Fool5d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Eli Lilly is experiencing explosive growth thanks ... According to data compiled by Coherent Market Insights, the global oncology drug market is expected to be worth $533 billion by 2031 ...
Is Eli Lilly and Company (LLY) the Best Stock to Buy in 2025 for Beginners?
Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...
This Chinese MIT Physicist Uses AI To Find New Drugs. Next Up: Solar Panels And EV Batteries
Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...
Pfizer succeeds in late-stage trial for colorectal cancer therapy
Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...
pharmaphorum2d
Lilly nets Scorpion cancer drug in $2.5bn licensing deal
Eli Lilly has unveiled a $2.5 billion ... having previously been working on LOXO-783, a drug it acquired as part of its $8 billion takeover of Loxo Oncology in 2019, but jettisoned last year ...
Business Today5d
Eli Lilly plans to expand its pipeline to address obesity-related conditions in India, says top executive
BT: Are there other drugs in Eli Lilly’s pipeline targeting obesity ... which includes medicines for cardiometabolic health, oncology, immunology, and neuroscience.